Smartest Doc
Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care
The Lancet Infectious Diseases, 08/21/2012
Pearlman BL – The viral resistance has become an important issue, essentially precluding use of protease inhibitor monotherapy, and potentially restricting future treatment options for patients who consequently do not achieve sustained virological response. Protease inhibitors are the first of many antiviral medications that will probably be combined in future interferon–free regimens.